Metrics to compare | ALOPM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALOPMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −2.4x | −0.2x | |
PEG Ratio | - | −0.05 | 0.00 | |
Price/Book | 1.2x | −0.2x | 2.6x | |
Price / LTM Sales | 2.6x | 7.8x | 2.8x | |
Upside (Analyst Target) | - | 211.8% | 62.7% | |
Fair Value Upside | Unlock | 9.7% | 8.0% | Unlock |
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers under PROMETHE brand; Nanocyclix, a kinase inhibitors, as well as on developing treatment for pancreatic and other cancers. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.